Original Article
Copyright ©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 28, 2011; 17(48): 5260-5266
Published online Dec 28, 2011. doi: 10.3748/wjg.v17.i48.5260
Table 1 Outcomes of immunotherapy in the study group
Patient no.SexAge (yr)Pre-treatment KPSNo. of injectionDTH positive5 mmAdverse eventsTumor markers AFPImaging responseSurvival months till now
1F3870460 mmFever, rashDecreasePD14.4D
2M46 100570 mmFever, rash, erythemaDecreasePD19.6A
3M5575645 mmFever, multiple erythemaDecreasePR18.8A
4M6590260 mmFeverDecreaseNC16.8D
5M7270525 mmFever, rashDecreaseNC15.2D
6M7890665 mmFatigue, feverDecreasePR16.0D
7M4080460 mmFever, rashDecreaseNC15.6D
8M547065 mmFeverIncreasePD17.6D
9F6395750 mmRashDecreasePR20.0A
Table 2 Ratios of post- and pre-immunotherapy in cell populations and interferon-γ expression levels
Patient no.CD8+post vs preCD45RO+post vs preCD56+post vs preIFN-γfold increasepost vs pre
15.096.784.8115.32
25.224.975.6612.25
36.333.784.7712.45
44.811.421.3911.11
52.152.432.173.88
63.673.665.867.94
73.783.942.818.31
80.552.020.651.03
95.236.673.5512.73